Patient Guide: Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 9 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06784648
Status: 🟢 Enrolling Now
Condition: Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent, Melanoma Stage III or IV, Melanoma, Melanoma Negative for bRAF, Melanoma Negative for nRAS, Melanomas, Uveal Melanoma, Metastatic
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 9 locations across the country.

Top locations include:
  • • Berlin,
  • • Essen,
  • • Heidelberg,
  • • And 6 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma - Join Clinical Trial NCTNCT06784648

How to Join This Clinical Trial - NCTNCT06784648

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent, Melanoma Stage III or IV, Melanoma, Melanoma Negative for bRAF, Melanoma Negative for nRAS, Melanomas, Uveal Melanoma, Metastatic. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent, Melanoma Stage III or IV, Melanoma, Melanoma Negative for bRAF, Melanoma Negative for nRAS, Melanomas, Uveal Melanoma, Metastatic. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent, Melanoma Stage III or IV, Melanoma, Melanoma Negative for bRAF, Melanoma Negative for nRAS, Melanomas, Uveal Melanoma, Metastatic
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06784648 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 9 locations. Find a study site near you:

Clinical Research Site

Berlin, - Germany

Status: RECRUITING

Clinical Research Site

Essen, - Germany

Status: RECRUITING

Clinical Research Site

Heidelberg, - Germany

Status: RECRUITING

Clinical Research Site

Mannheim, - Germany

Status: RECRUITING

Clinical Research Site

Barcelona, - Spain

Status: RECRUITING

Clinical Research Site

Madrid, - Spain

Status: RECRUITING

Clinical Research Site

London, Greater London W1G 6AD - United Kingdom

Status: RECRUITING

Clinical Research Site

Cardiff, Wales CF14 2TL - United Kingdom

Status: RECRUITING

Clinical Research Site

Manchester, M20 4BX - United Kingdom

Status: RECRUITING

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent, Melanoma Stage III or IV, Melanoma, Melanoma Negative for bRAF, Melanoma Negative for nRAS, Melanomas, Uveal Melanoma, Metastatic:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships